The final milestone came in December 2014. Sitting in a dim examination room, John read the fifth line of the Snellen chart: 20/40. Not perfect, but functional. His optic nerves showed residual scarring, but the inflammation was gone. The doctor said six words John will never forget: “You have regained functional sight, Mr. Sutton.”
The first sign of change came on day three of the IV steroids. John was sitting in a hospital cafeteria, sipping black coffee from a styrofoam cup. He turned his head toward a window—and saw a smear of blue. Not gray. Not dark. Blue.
It was hazy, like looking through wax paper. But it was color. It was light. It was the first flicker of a current returning.
But John was an electrician. He knew that darkness is just the absence of current. And somewhere, he believed, a circuit could be reconnected.
He froze. “Margaret,” he whispered. “The sky. I see the sky.”
In April 2014, a new specialist at St. Thomas’ Hospital in London proposed a radical theory: John might have a rare form of autoinflammatory optic neuropathy triggered by a dormant virus—specifically, varicella-zoster (the chickenpox virus) reactivating in his optic nerves without any rash. The treatment was aggressive: high-dose intravenous steroids for five days, followed by six months of an experimental monoclonal antibody therapy called epratuzumab, which targeted B-cells attacking his nerve sheaths.
